Check nelarabine plus chemotherapy for T-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of chemotherapy with nelarabine in people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It may help by improving remission in newly diagnosed or certain previously treated patients whose disease did not respond after one initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell ALL or T-cell lymphoblastic lymphoma (not a different type of cancer)
- You are newly diagnosed or your first round of induction chemotherapy failed, or you are in remission after 2 or fewer treatment courses
- You can function day to day at a level doctors rate as 0 to 3 (not fully independent but able to receive treatment)
- Your liver blood tests are not too abnormal (bilirubin within limits, and SGOT/SGPT within about 4 times the usual upper limit)
- Your kidney blood test (creatinine) is within limits (about 2.0, sometimes up to 2.5 if the tumor is affecting it)
- You are not pregnant and not nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This trial tests if adding a targeted drug called daratumumab to standard chemotherapy works better for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab helps the immune system find and attack cancer cells.
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Hear when a new T Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.